Mitigating Progression of Liver Fibrosis in HIV/HCV Coinfection

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center in Chicago, IL. She received her medical degree from The Ohio State University College of Medicine in Columbus, where she completed a residency and fellowship in gastroenterology/hepatology followed by a second fellowship in advanced transplant hepatology at Johns Hopkins Hospital in Baltimore, MD. Her primary research interests focus on viral hepatitis – from both drug development and a clinical perspective – liver transplantation, and complications of chronic liver disease.

Prof. Reau has been an invited lecturer at numerous presentations focused on viral hepatitis, fatty liver disease, cirrhosis, and liver transplantation. Prof. Reau is a fellow of the American Gastroenterological Association and American Association for the Study of Liver Diseases (AASLD). Additionally, she is the current editor in chief of CLD (Clinical Liver Disease) and was an author of the AASLD/IDSA hepatitis C guidance document. She was the committee chair of the AASLD public policy committee and a member of the AASLD practice guideline committee for four years.

Prof. Reau has authored or coauthored more than 100 peer-reviewed articles that have been published in journals such as Hepatology, Hepatitis Research and Treatment, and Clinics in Liver Disease. She is Co-chair of the National ALF Medical Advisory Committee and sits on multiple advisory boards. She is currently a member of the steering committee for the hepatitis C special interest group (SIG) for the American Association for the Study of Liver Diseases (AASLD) and a member of the ACG training committee.

Dr. Ramers is the Chief of Population Health and Director of Graduate Medical Education at the Family Health Centers of San Diego (FHCSD), a large Federally Qualified Health Center (FQHC) system serving nearly 200,000 medically underserved individuals throughout San Diego county. He is board certified in Internal Medicine, Infectious Diseases, and Addiction Medicine, and is particularly interested in HIV, HBV, HCV, and service of medically underserved, immigrant, and refugee populations. He co-chairs the California Chapter of the American Academy of HIV Medicine and has advocated for HIV/HCV care at the state legislative level. Dr. Ramers has served as a consultant for CDC- sponsored HIV/HBV/HCV educational projects in Asia and Africa. Since 2018 he has served as the Senior Clinical Advisor for the Clinton Health Access Initiative’s Global Hepatitis Program, working to eliminate HBV and HCV in seven partner countries in Asia and Africa.

Since the onset of the COVID-19 pandemic, Dr. Ramers has taken on a leadership role in policy, laboratory, public health, research, and clinical response. He is a core member of FHCSD’s COVID-19 Response Efforts team, delivering biweekly updates to > 200 clinicians and staff. At the regional level he serves on the county Clinical Vaccine Advisory Committee and Equity task forces. He is a member of the national IDSA-CDC clinical call escalation volunteer group. He has facilitated several telemedicine forums including one on HIV care at the International AIDS Conference, a 10-week intensive telemedicine series (Telemedicine Hack) supported by HHS, and a COVID-19 outpatient therapeutics series supported by HHS and Project ECHO. Internationally, Dr. Ramers facilitates a twice-weekly Spanish-language COVID-19 virtual community of practice for Latin America and has presented at an international WHO AFRO region webinar on SARS-CoV-2 transmission.

Dr. Lim is a Professor of Medicine and Vice-Chief of the Section of Digestive Diseases at Yale University, where he serves as Director of Clinical Hepatology and Associate Chief of Yale-New Haven Health System (YNHHS) Digestive Health. He is a graduate of the Feinberg School of Medicine at Northwestern University (Chicago, Illinois, USA), and completed training in Internal Medicine at Yale University (New Haven, Connecticut, USA), and Gastroenterology and Hepatology at Stanford University (Palo Alto, California, USA). In his role at the Yale Liver Center, he conducts patient-oriented research evaluating clinical outcomes in chronic liver disease and runs an active clinical trials program examining novel investigational agents for viral hepatitis and NASH. He has held numerous leadership roles for the AASLD, AGA, and the ACG, and serves as Chair of the EPIC Gastroenterology Specialty Steering Board.